Testing azirkitug for lung, head/neck, and other solid cancers
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin clinical trials.
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have a recent tumor biopsy or stored tumor tissue from within the last 6 months
- Be able to do daily activities fairly well (ECOG 0–1) and expected to live at least 3 months
- Have measurable cancer that can be tracked on scans/tests
- Your cancer type must match one of these: NSCLC, head and neck squamous cell cancer, MSS colorectal cancer, stomach/GEJ cancer, high-grade serous ovarian cancer, pancreatic adenocarcinoma, or triple-negative breast cancer with specific prior treatment history
- Blood counts and other lab tests must meet study thresholds (you may need additional lab checks)
- Must not have certain major health risks (examples include recent major surgery, pregnancy, active autoimmune disease, or certain blood-clot risks for pancreas cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
This Phase 1/2 study tests a new AstraZeneca cancer drug (AZD5335) to see how safely it can be given and how well it works in people with advanced solid tumors. You may get it alone or with another treatment, and you’ll need to provide tumor information (sometimes including a biopsy) for study planning.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This trial is testing a new medicine, AZD9793, for people with advanced or metastatic solid tumors that have a specific marker called GPC3. The goal is to see if AZD9793 can help shrink or control the cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.